[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588225":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":19,"locations":28,"responsibleParty":42,"collaborators":18,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":18,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":30,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Changi General Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"mass spectrometry analysis","EXPERIMENTAL","All patients will be collected 50mls of urine for mass spectrometry analysis to determine medication adherence during each study visit; on enrolment, at 3-month, and at 6-month period.",[13],"Other: mass spectrometry analysis",[15],{"type":6,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"The collected urine samples will be analyzed to determine medication adherence during study visits",[9],null,[20,25],{"name":21,"role":22,"phone":23,"phoneExt":18,"email":24},"Sumitro Harjanto, MD MRCP","CONTACT","+6564267818","sumitro.harjanto@singhealth.com.sg",{"name":26,"role":22,"phone":23,"phoneExt":18,"email":27},"Geraldine Lim","geraldine.lim.x@singhealth.com.sg",[29],{"facility":5,"status":30,"city":31,"state":18,"zip":18,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Singapore","SG",{"type":34,"coordinates":35},"Point",[36,37],103.85007,1.28967,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":41,"phoneExt":18,"email":24},"+65",{"type":43,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100588225","addressing-medication-non-adherence-in-patients-with-poorly-controlled-hypertension-using-urine-mass-spectrometry-100588225",false,"NCT06938633","Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension Using Urine Mass Spectrometry","Utility of Urine Mass Spectrometry Analysis in Addressing Medication Non-adherence in Patients With Poorly Controlled Hypertension","ADURINE","Inclusion Criteria:\n\n1. Age of 21 - 80 years\n2. Systolic blood pressure of ≥140 mmHg or average systolic blood pressure ≥135 mmHg, or diastolic blood pressure ≥90 mmHg or average diastolic blood pressure ≥85 mmHg, on at least two measurements\n3. Currently taking 2 or more hypertension medications\n4. Able to provide informed consent.\n\nExclusion Criteria:\n\n* Significant kidney impairment with eGFR of less than 45mL\u002Fmin\u002F1.73m2 or on dialysis\n* Known history of chronic liver disease","ALL","21 Years","80 Years",{"count":56,"type":57},100,"ESTIMATED","INTERVENTIONAL",[60],"NA","* Hypertension is the single largest contributor to cardiovascular disease and death. While adequate control of hypertension reduces risk of disease, many patients have uncontrolled hypertension. This is often due to medication non-adherence. Left undetected, patients are prescribed additional medications, and referred to multiple specialists for investigations - leading to increased healthcare costs. Hence, detecting non-adherence to antihypertensive medications is important. However, patient history, patient recall, or questionnaires, are often inaccurate. Most recently, urine measurements of antihypertensive drug levels, using mass spectrometry, has been established as the gold standard to assess medication adherence. The one-time urine test for medication adherence is ideal: It's convenient, non-invasive, economical, and can be easily performed in a clinic setting. By improving blood pressure control, this will lead to reductions in healthcare visits, avoidance of catastrophic cardiovascular events. Ultimately, this translates to significant economic savings for both patients with hypertension and the healthcare system.\n* Therefore, the investigators hypothesize that the implementation of urine adherence testing coupled with targeted counselling will improve the adherence and blood pressure control in hypertension. To do this, the investigators aim to (1) evaluate for medication adherence in 312 participants with recent stroke and hypertension; (2) evaluate for medication non-adherence in participants with uncontrolled hypertension; and (3) assess if detection of non-adherence can improve hypertension control.",[63,64,65],"Hypertension","Uncontrolled Hypertension","Non-Adherence, Medication",[67,68,69],"Urine mass spectrometry","Uncontrolled hypertension","Medication non-adherence","2025-04-14",{"date":72,"type":73},"2025-04-22","ACTUAL",{"date":75,"type":73},"2024-02-07",{"date":77,"type":57},"2025-09-30",{"name":5,"class":6},1]